FreeStyle Libre is a continuous glucose monitoring (CGM) system. It uses a sensor to read and check a person’s glucose levels. People with diabetes can use FreeStyle Libre to help manage the condition ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the ...

Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c ...